Detalhe da pesquisa
1.
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
Blood
; 133(14): 1548-1559, 2019 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30658992
2.
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
N Engl J Med
; 377(5): 454-464, 2017 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28644114
3.
A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance).
Biol Blood Marrow Transplant
; 25(10): 1984-1992, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31212080
4.
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.
Blood
; 129(13): 1763-1767, 2017 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28082441
5.
Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).
Pediatr Blood Cancer
; 66(3): e27542, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30393935
6.
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Blood
; 124(4): 536-45, 2014 Jul 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-24914135
7.
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
Am J Hematol
; 90(12): 1106-10, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26331432
8.
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.
Blood
; 119(21): 4860-7, 2012 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-22504925
9.
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
Blood
; 119(23): 5397-404, 2012 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-22493299
10.
Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.
Cancer
; 119(2): 363-70, 2013 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22760587
11.
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Blood
; 118(11): 2970-5, 2011 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21690557
12.
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Br J Haematol
; 156(3): 326-33, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22107129
13.
Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).
Ann Hematol
; 91(1): 33-8, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21538061
14.
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
Pediatr Blood Cancer
; 59(4): 662-7, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22378655
15.
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
Am J Hematol
; 86(8): 640-5, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21630308
16.
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.
Blood Adv
; 5(2): 504-512, 2021 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33496745
17.
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
Leukemia
; 35(9): 2539-2551, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33654204
18.
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.
Blood Adv
; 4(4): 696-705, 2020 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32092139
19.
Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis.
Blood Cancer J
; 10(1): 4, 2020 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31913261
20.
Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
Br J Haematol
; 167(4): 563-5, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24974945